IRIS - Res&Arch Institutional Research Information System - Research & Archive

MANDALA', Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.438
EU - Europa 1.409
AS - Asia 433
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 7
SA - Sud America 7
AF - Africa 1
Totale 5.315
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.433
IE - Irlanda 718
IT - Italia 446
VN - Vietnam 273
HK - Hong Kong 103
RU - Federazione Russa 85
DE - Germania 36
UA - Ucraina 29
SE - Svezia 22
EU - Europa 20
FI - Finlandia 20
TR - Turchia 18
GB - Regno Unito 17
SG - Singapore 17
CN - Cina 9
GR - Grecia 9
FR - Francia 6
AU - Australia 5
CH - Svizzera 5
CL - Cile 5
UZ - Uzbekistan 5
AT - Austria 4
CA - Canada 4
NL - Olanda 4
PL - Polonia 4
JP - Giappone 3
BR - Brasile 2
LB - Libano 2
NZ - Nuova Zelanda 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
BE - Belgio 1
CZ - Repubblica Ceca 1
EG - Egitto 1
MX - Messico 1
RS - Serbia 1
SI - Slovenia 1
Totale 5.315
Salva come PNG Salva come JPEG
Città #
Chandler 947
Dublin 717
Dong Ket 273
Altamura 269
San Mateo 234
Medford 216
Princeton 213
Lawrence 207
Andover 187
Wilmington 122
Los Angeles 110
Hong Kong 98
Arezzo 57
Redwood City 57
Des Moines 45
Norwalk 42
San Paolo di Civitate 39
Redmond 23
Ashburn 19
Kocaeli 16
Helsinki 14
Saint Petersburg 14
Jacksonville 10
Singapore 8
Moscow 6
Perugia 6
Chicago 5
Milan 5
Den Haag 4
Florence 4
Philadelphia 4
Treviso 4
Woodbridge 4
Ancona 3
Falls Church 3
Frankfurt Am Main 3
Kiev 3
New York 3
Padova 3
Santiago 3
St Petersburg 3
Cleveland 2
Dueville 2
Hanover 2
Houston 2
Izmir 2
Lappeenranta 2
Las Vegas 2
Ludwigshafen 2
Melbourne 2
Montreal 2
Ostra Vetere 2
Portland 2
Rome 2
Taipei 2
Terni 2
Tokyo 2
Wernigerode 2
Andria 1
Ann Arbor 1
Auckland 1
Augusta 1
Baltimore 1
Bergamo 1
Brisbane 1
Brussels 1
Cairo 1
Cambridge 1
Cannock 1
Carbonia 1
Cheyenne 1
Colindale 1
Conshohocken 1
Council Bluffs 1
Cumberland 1
Dieppe 1
Esslingen am Neckar 1
Fairfield 1
Gatchina 1
Gunzenhausen 1
Kai Yi Wan 1
Kemerovo 1
Kilburn 1
Ljubljana 1
London 1
Mallow 1
Medowie 1
Mexico City 1
Moggio 1
Nanjing 1
Naples 1
Napoli 1
Newton Stewart 1
Paris 1
Pavia 1
Perth 1
Piraeus 1
Queenstown 1
Quinto Vicentino 1
Rio de Janeiro 1
Totale 4.079
Salva come PNG Salva come JPEG
Nome #
Chemotherapy-associatedthromboembolic risk in cancer outpatients and effect of nadroparinthromboprophylaxis: results of a retrospective analysis of the PROTECHT study. 47
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism 47
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 45
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 triaL 45
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial 44
Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703 44
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 43
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial 41
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 41
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma 41
Acute endocrine effects of interleukin-12 in cancer patients 40
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin 40
Adjuvant therapy in breast cancer and venous thromboembolism 40
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial 40
Tissue prognostic biomarkers in primary cutaneous melanoma 39
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management 39
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma 39
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival 38
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling 37
A prospective study on survival in cancer patients with and without venous thromboembolism. 36
40. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH 36
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 36
Acute dyspnea due to right phrenic palsy during infusional chemotherapy 36
AKT-ions with a TWIST between EMT and MET 36
Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives 35
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial 35
Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients 35
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma 35
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1 35
Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma 35
Insights Into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1 34
Adjuvant therapy of colon cancer. State of the art and future perspectives 34
Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma 34
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee 33
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action 33
Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications 32
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i 32
GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis 32
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study 32
Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome 31
Treatment of venous thromboembolism in cancer patients: The dark side of the moon 31
Melanoma brain metastases: review of histopathological features and immune-molecular aspects 30
Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study 30
Squamoproliferative skin lesion during braf inhibitors:one size does not fit all 30
Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study 30
Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia 30
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? 30
Venous thromboembolism and cancer: new issues for an old topic 29
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status 29
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial 29
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition 29
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis 29
Bisphosphonates and metastatic bone disease 29
Chemotherapy for metastatic breast cancer 29
MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortiuM 29
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib 29
Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases 29
Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients 29
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS) 29
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic 28
Is there a right-sided shift for colorectal cancer in women compared with men? 28
Buprenorphine-induced acute respiratory depression during ifosfamide-based chemotherapy 28
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma 28
Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? 28
Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up 28
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial 28
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program 28
Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia 28
HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear? 28
What is the real benefit of adjuvant chemotherapy in the Adjuvant Navelbine International Trialist Association trial? 28
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial 28
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer 28
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 28
Mediastinal lymphoadenopathy in a patient with breast cancer 28
Targeted therapy for advanced cutaneous melanoma 27
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. 27
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: A multicenter international retrospective study 27
Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action 27
Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2 27
Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic disease 27
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma 27
The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma 27
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 27
A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday 27
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings 26
An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system 26
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma 26
The density and spatial tissue distribution of CD8+ and CD163+immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors 26
Unexpected right phrenic nerve injury during 5-fluorouracil continuous infusion plus cisplatin and vinorelbine in breast cancer patients 26
Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study 26
Chemoradiotherapy for rectal cancer 26
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux 26
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases 26
Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer 26
Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma 26
Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management 25
Self-monitoring versus standard monitoring of oral anticoagulation 25
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) 25
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p 25
BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome 25
Totale 3.167
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.383
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.383
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192 0 0 0 0 0 0 0 0 0 0 2 0
2019/202011 0 0 2 0 2 0 2 0 3 0 2 0
2020/2021671 0 2 0 2 12 1 270 6 19 51 16 292
2021/20221.193 8 228 9 2 18 7 31 447 9 44 165 225
2022/20233.048 218 524 28 237 275 391 0 166 1.066 9 95 39
2023/2024737 87 154 53 28 18 5 141 9 94 121 27 0
Totale 5.671